<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Orthopaedics</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F895A43A-B58D-4BAF-875C-FC87AF31A2E5"><gtr:id>F895A43A-B58D-4BAF-875C-FC87AF31A2E5</gtr:id><gtr:firstName>Umber</gtr:firstName><gtr:surname>Cheema</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FF023774%2F1"><gtr:id>D982C06A-743C-4729-B0FE-475E1E76D194</gtr:id><gtr:title>Understanding how to engineer Oxygen-dependent angiogenesis in 3D tissue models</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>BB/F023774/1</gtr:grantReference><gtr:abstractText>Tissue engineering (TE) provides a valuable tool for the surgical repair of damaged body tissue, but designing TE constructs in which cells can survive to aid repair depends heavily on ensuring that these cells receive an adequate supply of O2 and nutrients. The cells residing in any piece of human tissue determine its architecture and function. In the core of tissues, O2 levels are limiting, therefore cells signal to surrounding vessels to infiltrate thereby increasing supply of crucial factors, a process called angiogenesis. This process is difficult to understand as the tissues of the body are complex, so I propose a model to correlate exposure of cells to O2 to help identify important cell specific signals crucial in the process of angiogenesis. By removing cells from tissue and growing them in well defined 3D collagen scaffolds, cell behaviour corresponding to specific positions within a scaffold, with information on the O2 levels triggering this signalling, can be identified. It is crucial to understand cell responses in a 3D environment, as this is the native environment in which cells reside. There are currently few tools at the disposal of researchers that enable them to examine how cells respond to the changing O2 environment during construction and implantation of repair devices. Cell embedded dense collagen sheets, will be spiralled to form 3D constructs. Over time periods of up to 1 month, I will measure O2 levels in the core and other specific regions of the 3D construct using O2 probes, and when these 3D spiralled constructs are unrolled, areas corresponding to known O2 levels will be dissected and examined, resulting in the identification of critical cell responses in relation to their position in a 3D construct, creating a 'map' of cell response dependent upon O2 exposure. These responses can then be manipulated, by controlling exposure of cells to certain O2 levels known to result in upregulation of markers which will aid survival of a construct in the body following implantation. Different biomaterials and composites will be then tested, for different tissue constructs. This model will then test whether specialised Endothelial Cells are attracted by core cell signalling and whether they form vessels, crucial for vascularisation. There is a critical balance to achieve to manipulate cell response: the correct level of O2 exposure to exploit natural cell behaviours. My hypothesis is that cells in the core of 3D TE collagen scaffolds, exposed to low-level O2, will produce important angiogenic signalling molecules, which will attract host vessels into the 3D construct core when implanted in vivo, therefore ensuring survival of a TE construct. The success of this approach will culminate in in vivo studies testing the angiogenic potential of such cellular TE devices. This new and innovative approach will help our understanding of how cells respond in their native 3D environment to different O2 exposure; how this translates to different signalling to induce angiogenesis; and how this information can be manipulated to help survival and maturation of TE constructs for future implantation to replace diseased and injured tissues. Without an understanding of how successful integration and survival of 3D TE constructs can be achieved in vivo, making replacement tissues cannot be a realistic goal.</gtr:abstractText><gtr:technicalSummary>Current concepts based primarily on tumour research are that cells do not survive &amp;gt;2mm in cell dense organs without vascularisation. The main objective of this study is to challenge conventional views on cell survival in the core of tissue engineered (TE) constructs, which suffer from poor perfusion of O2 and nutrients resulting in cell death. An innovative approach is to use native collagen type I scaffolds, where O2 levels in the core are low but limited cell death occurs. By manipulating material properties of TE constructs, O2 levels can be controlled to exploit the natural cell response to increase angiogenic signalling, to result in TE devices that attract angiogenesis in vivo, aiding survival. I will develop tissue models for investigating the control and generation of angiogenic signals, resulting in successful TE constructs with predictable angiogenic outcome. I will quantitatively define a 3D model to test the interplay of cell/matrix density and diffusion distance on O2 levels and correlate this to cell manufactured angiogenic signals, utilising a cross-disciplinary approach. This will be done using luminescent O2 gradient probes being developed by Oxford OptronixTM and the host institution. Over a 1 month period O2 levels in the core and distinct spatial positions in such constructs will be measured, and when constructs are unfurled and dissected, quantitative measurements of different angiogenic markers can be mapped alongside O2 measurements. The hypothesis being that 'deeper-lying' cells in the core, exposed to low-level O2, will up-regulate angiogenic markers, with a gradient up till the surface. Control experiments will see constructs cultured at physiological O2 levels of tissues in vivo, by utilising gas-mixing chambers. The regulation of angiogenic markers under these conditions compared to standard cultures will indicate responses expected in vivo. Validation of the angiogenic potential of 3D cell/matrix constructs will be conducted in vivo.</gtr:technicalSummary><gtr:fund><gtr:end>2014-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2008-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>556147</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yale University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>YALE-UCL collaborative</gtr:description><gtr:id>5ACFF114-76B8-4223-8E0B-AD7C4E44FCE6</gtr:id><gtr:impact>Our first paper has been accepted in regenerative Medicine.

we had a R21 grant rejected, but are writing a new grant to Diabetes UK for this June.</gtr:impact><gtr:outcomeId>56e0274250b0a5.35914936-1</gtr:outcomeId><gtr:partnerContribution>Prof Alan Dardik is an expert in animal models of diabetes, and we tested a novel ulcer patch to aid healing of diabetic wounds. We developed and engineered them at UCL and sent them to him for implantation.</gtr:partnerContribution><gtr:piContribution>We have had a student exchange. All the animal work was carried out by yale, and paid for by them.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Impact scheme</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Oxford Optronix Ltd</gtr:fundingOrg><gtr:id>884F4B5C-3420-4640-940C-05C649CEA2A1</gtr:id><gtr:outcomeId>56e02a2e12f265.28121565</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>i4i</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef> II-LA-0813-20002</gtr:fundingRef><gtr:id>54F31006-D38E-4C63-A199-3D6F44566AF8</gtr:id><gtr:outcomeId>56e02b3c802d39.59327866</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>72000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL-EPSRC</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>3A7CE5EE-CDDC-4B38-AE28-3CD4D7D2E116</gtr:id><gtr:outcomeId>56e02c45cfa4b4.12544749</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>74000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Impact scheme</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>TAP Biosystems</gtr:fundingOrg><gtr:id>2530312A-C485-4438-A529-24232D1D2020</gtr:id><gtr:outcomeId>56e02a79785cf2.45301594</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>69883</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SCAT Bone Cancer Trust</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>SCAT Bone Cancer Trust</gtr:fundingOrg><gtr:id>8BA9247D-BA79-4100-A218-C5AF3156C4A4</gtr:id><gtr:outcomeId>56e02b97635cc8.57307160</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>We have spent some time setting up workshops to demonstrate the importance of developing humanised models of tumour progression to further our understanding of cancer and the effect specific therapies can have on cancers</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>E762B328-2A38-49C7-90BC-41850E2F8C8C</gtr:id><gtr:impactTypes><gtr:impactType>Cultural,Societal</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56e0431230d482.61820151</gtr:outcomeId><gtr:sector>Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have engineered a collagen scaffold to keep cells viable, create levels of hypoxia which stimulate the cells to release angiogenic growth factors. these factors are originally trapped in the collagen then gradually released. We have just tested these in a diabetic rat model, with positive impact on healing of diabetic ulcers.</gtr:description><gtr:exploitationPathways>I am currently putting forward a grant alongside Dr Janice Tsui, who runs the diabetic foot clinic at the Royal Free hospital to gather enough preliminary safety data to apply for a clinical trail for our engineered patch's.</gtr:exploitationPathways><gtr:id>F5E948A3-2948-4A49-878D-820F7F45FC5B</gtr:id><gtr:outcomeId>56e0299fede643.14432898</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This research has resulted in the development of 3D models of tumour in vitro. We are testing cancer drugs to see whether we can measure therapeutic intervention on this model.</gtr:description><gtr:id>38C877A6-5EEC-4E79-9C6A-96B886AF4964</gtr:id><gtr:impact>This model is used by multiple groups in Medical Physics at UCL as models to develop MRI imaging for cancers and to test radiotherapy.</gtr:impact><gtr:outcomeId>56e041d2b58ca4.97648995</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>3D Tumouroid to replace PDX</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AA5140C4-96CC-472F-AEB6-576CB813ECAB</gtr:id><gtr:title>Effects of photochemical riboflavin-mediated crosslinks on the physical properties of collagen constructs and fibrils.</gtr:title><gtr:parentPublicationTitle>Journal of materials science. Materials in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5c3194e9cac083413f5fc315e1505c5"><gtr:id>d5c3194e9cac083413f5fc315e1505c5</gtr:id><gtr:otherNames>Rich H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0957-4530</gtr:issn><gtr:outcomeId>56e020c460d010.75629231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6180F989-49D6-4CAE-B03C-06065D82B073</gtr:id><gtr:title>Oxygen diffusion through collagen scaffolds at defined densities: implications for cell survival in tissue models.</gtr:title><gtr:parentPublicationTitle>Journal of tissue engineering and regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7de8bf22a59e0dc54f0eb111f4fc2989"><gtr:id>7de8bf22a59e0dc54f0eb111f4fc2989</gtr:id><gtr:otherNames>Cheema U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6254</gtr:issn><gtr:outcomeId>56e021c3bec021.82757404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63F4FC91-35DA-4F30-8F58-D641585BA640</gtr:id><gtr:title>Hyaluronan hydration generates three-dimensional meso-scale structure in engineered collagen tissues.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c16c5f479e3899cefda351da6e95ef87"><gtr:id>c16c5f479e3899cefda351da6e95ef87</gtr:id><gtr:otherNames>Anandagoda N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>56e020c4e6df75.32397283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15DD956F-D4BF-42BA-9AB0-E0FBD4A03ECA</gtr:id><gtr:title>A novel tissue engineered three-dimensional in vitro colorectal cancer model.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ae62560c7f47dd9a0d1fe50275d9dc"><gtr:id>d4ae62560c7f47dd9a0d1fe50275d9dc</gtr:id><gtr:otherNames>Nyga A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn><gtr:outcomeId>56e020c4838cf9.66774862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB022028-D5F5-47F2-8D8C-BC2EE9A6F16A</gtr:id><gtr:title>Laminin promotes vascular network formation in 3D in vitro collagen scaffolds by regulating VEGF uptake.</gtr:title><gtr:parentPublicationTitle>Experimental cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d3c09ab5126d2eb4cb229f7f8897ed9"><gtr:id>8d3c09ab5126d2eb4cb229f7f8897ed9</gtr:id><gtr:otherNames>Stamati K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-4827</gtr:issn><gtr:outcomeId>56e020c43f8e82.18509645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18F338AA-06E1-4077-8AB9-CDC9C4514C79</gtr:id><gtr:title>Alignment hierarchies: engineering architecture from the nanometre to the micrometre scale.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cbcb4f41045355905aca092b92a0c5f"><gtr:id>3cbcb4f41045355905aca092b92a0c5f</gtr:id><gtr:otherNames>Kureshi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>56e021c4f0f0b5.67900100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>502F7EB5-C3BF-4EE0-B34B-CE0584E74CA3</gtr:id><gtr:title>Oxygen consumption rate of cells in 3D culture: the use of experiment and simulation to measure kinetic parameters and optimise culture conditions.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb07442ef761872b2426f96a9c55a967"><gtr:id>bb07442ef761872b2426f96a9c55a967</gtr:id><gtr:otherNames>Streeter I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>56e0218194e716.80544201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DF2CAB4-4E21-4590-A77E-734E9D5749F9</gtr:id><gtr:title>3D tumour models: novel in vitro approaches to cancer studies.</gtr:title><gtr:parentPublicationTitle>Journal of cell communication and signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ae62560c7f47dd9a0d1fe50275d9dc"><gtr:id>d4ae62560c7f47dd9a0d1fe50275d9dc</gtr:id><gtr:otherNames>Nyga A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1873-9601</gtr:issn><gtr:outcomeId>56e02181b67989.68902407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>896E7413-9D73-453C-97A3-570FE39DA90C</gtr:id><gtr:title>Quantifying the correlation between spatially defined oxygen gradients and cell fate in an engineered three-dimensional culture model.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0e2623fc7f905d6ce7f9a950d82ac03"><gtr:id>c0e2623fc7f905d6ce7f9a950d82ac03</gtr:id><gtr:otherNames>Ardakani AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>56e020c4172cf3.72333796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22C5932F-77EE-4E79-8697-A4705FC9808E</gtr:id><gtr:title>A 3D in vitro cancer model as a platform for nanoparticle uptake and imaging investigations.</gtr:title><gtr:parentPublicationTitle>Small (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b42e1898d6918d48e88a32ff8cee33c1"><gtr:id>b42e1898d6918d48e88a32ff8cee33c1</gtr:id><gtr:otherNames>Ricketts KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1613-6810</gtr:issn><gtr:outcomeId>56e020c3e7cd91.52943250</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52952A68-735D-4D50-919A-4F3569666A09</gtr:id><gtr:title>Delivery of mesenchymal stem cells in biomimetic engineered scaffolds promotes healing of diabetic ulcers.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1c12de314374ebcb4e8ee971d105c75"><gtr:id>d1c12de314374ebcb4e8ee971d105c75</gtr:id><gtr:otherNames>Assi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>58c7c2f8676fb3.17130054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB08BF1F-AD91-476B-BDC9-B0BD6B6C4C4D</gtr:id><gtr:title>First implantable device for hypoxia-mediated angiogenic induction.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2744a196d98dbf828d57722667e2747a"><gtr:id>2744a196d98dbf828d57722667e2747a</gtr:id><gtr:otherNames>Hadjipanayi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>56e02181d45d37.67258994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77352194-7BC7-4596-ADCD-068AB5A8EEB2</gtr:id><gtr:title>Less is more: new biomimetic approach to control spatial and temporal cell loading for tissue engineering.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical materials research. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/196b2085b3d0b2201189af9a269b3c51"><gtr:id>196b2085b3d0b2201189af9a269b3c51</gtr:id><gtr:otherNames>Deng D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-3296</gtr:issn><gtr:outcomeId>585d331ba80320.48375944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B282E2A2-A0BA-4FD1-AC30-25490BCFCD08</gtr:id><gtr:title>Injectable system for spatio-temporally controlled delivery of hypoxia-induced angiogenic signalling.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2744a196d98dbf828d57722667e2747a"><gtr:id>2744a196d98dbf828d57722667e2747a</gtr:id><gtr:otherNames>Hadjipanayi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>56e020c4c39801.87130996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D8D17C1-9F32-456C-8E6A-77486F6E63F3</gtr:id><gtr:title>Mechanical anisotropy in compressed collagen produced by localised photodynamic cross-linking.</gtr:title><gtr:parentPublicationTitle>Journal of the mechanical behavior of biomedical materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fa8b55578ae3549c308c0b82f97896a"><gtr:id>9fa8b55578ae3549c308c0b82f97896a</gtr:id><gtr:otherNames>Wong JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1878-0180</gtr:issn><gtr:outcomeId>56e020c4a38ba4.86599868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A040F096-5547-4275-A91A-1C9ABCC74DA7</gtr:id><gtr:title>Controlling physiological angiogenesis by hypoxia-induced signaling.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2744a196d98dbf828d57722667e2747a"><gtr:id>2744a196d98dbf828d57722667e2747a</gtr:id><gtr:otherNames>Hadjipanayi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>56e021c51beb53.08591347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F0309DF-7920-4909-9ECE-BCFF4A6CCF6C</gtr:id><gtr:title>The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Journal of tissue engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/728780c7454af07766baebf48bff836d"><gtr:id>728780c7454af07766baebf48bff836d</gtr:id><gtr:otherNames>Magdeldin T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-7314</gtr:issn><gtr:outcomeId>56e02021d18bf6.80288943</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/F023774/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>